Centessa Pharmaceuticals Demonstrates Proof-of-Mechanism from First Three PiMZ Subjects Dosed in Part B of Phase 1 Study Evaluating ZF874

NEXT STORY
Statera Biopharma Honors Pancreatic Cancer Awareness Month
PREV STORY
Cabaletta Bio Reports Third Quarter 2021 Financial Results and Provides Business Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

AXIM Biotech Enters Clinical Study Agreement with University of British Columbia to Begin Clinical Trial On CBD Chewing Gum For Treatment of Drug-Related Psychosis

NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), ...

author_avatar
NASDAQ Market News

Idera Pharmaceuticals to Provide Multiple Presentations on Intratumoral IMO-2125 at the 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ...

author_avatar
NASDAQ Market News

Telix Pharmaceuticals and Atlab Pharma Conclude Therapeutic Product Development Agreement for Prostate Cancer

MELBOURNE, Australia and NANTES, France, Jan. 18, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited ...

author_avatar
NASDAQ Market News